Track topics on Twitter Track topics that are important to you
More than a year after the FDA rejected Amgen’s experimental osteoporosis drug due to safety concerns, the Thousand Oaks, CA, company has teed up a new application. The Amgen (NASDAQ: AMGN) drug, romosozumab (Evenity), is an antibody treatment meant to strengthen bones and reduce the chance that they could break. But while romosozumab did lower […]
Original Article: With New Data, Amgen Tries Again for FDA OK of Osteoporosis DrugNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...